comparemela.com

Latest Breaking News On - Code therapeutics - Page 6 : comparemela.com

Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders Equity Requirement and Continued Listing on The Nasdaq Stock Market Seite 1

31.01.2024 - BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) - TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has received notice from . Seite 1

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid

BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced a co-research agreement

Reviewing Verve Therapeutics (NASDAQ:VERV) and TransCode Therapeutics (NASDAQ:RNAZ)

Verve Therapeutics (NASDAQ:VERV – Get Free Report) and TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership. Valuation and Earnings This table compares Verve […]

TransCode Therapeutics Announces Closing of $7 25 Million Public Offering

BOSTON, Jan. 22, 2024 (GLOBE NEWSWIRE) TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the

TransCode Therapeutics Announces Closing of $7 25 Million Public Offering

TransCode Therapeutics Announces Closing of $7 25 Million Public Offering
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.